timothy sykes logo

Stock News

Is CGTX Stock About to Skyrocket?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 8/13/2025, 9:18 am ET 8/13/2025, 9:18 am ET | 5 min 5 min read
Is CGTX Stock About to Skyrocket? Thumbnail

Cognition Therapeutics Inc.’s stock rises 27.27% amid investor confidence following promising Alzheimer’s treatment results.

The recent news around Cognition Therapeutics Inc. (CGTX) has stirred up a lot of buzz among analysts and investors alike. Here’s a look into why the company’s stock might be ready for a significant leap.

  • The company shared promising results from their phase 2 “SHIMMER” study, showing significant improvements in patients with dementia with Lewy bodies and Alzheimer’s when compared to a placebo, signaling it as a potential game-changer.

Candlestick Chart

Live Update At 09:18:26 EST: On Wednesday, August 13, 2025 Cognition Therapeutics Inc. stock [NASDAQ: CGTX] is trending up by 27.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Promising Data from Clinical Trials

As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Understanding this is crucial for every trader. It’s not about the immediate wins but about developing a strategy that protects you from significant losses and allows you to learn and grow over time. By focusing on protecting your capital, you create an environment where you’re not constantly stressed about losses, enabling you to focus on improving your skills and identifying long-term opportunities in the market.

  • At the Alzheimer’s Association International Conference (AAIC 2025), Cognition Therapeutics revealed data showcasing Zervimesine’s broad neural impacts and its potential to counter cognitive deterioration in Alzheimer’s disease patients. This has put the spotlight firmly on their research.

  • In another significant announcement, the Phase 2 COG0202 study of Zervimesine reported promising neuroprotective effects, which speak volumes about the potential value the drug brings not only to patients but to investors too.

Q2 Earnings: What it Means for Investors

  • CGTX reported a Q2 EPS of -$0.11, slightly missing consensus expectations, but this hasn’t overshadowed their substantial clinical progress on therapies targeting age-related degenerative diseases. They highlighted advancements through clinical trials, which might explain the current exuberance surrounding the stock.

More Breaking News

Financially, CGTX’s recent earnings report was a mix of news. While it missed the expected earnings per share, the strong clinical progress positions the company well for future growth. Changes in cash flow revealed a cautious but strategic allocation of resources, highlighted by free cash flow of -$5.62M. A closer look at the balance sheet shows total assets at $19.622M, with a manageable debt-to-equity ratio of 0.06, indicating a solid financial foothold.

Recent Stock Performance

Trading activity has mirrored this hive of activity. On Aug 12, 2025, CGTX opened at $0.86 and closed at $1.10, showcasing a surge in investor confidence. In conjunction with a constructive partnership with the FDA, these results might catalyze sustained interest in the stock in the short to medium term.

The company’s price jumped significantly, reflecting its strategic clinical milestones. With asset turnover ratios and a steady incline in market interest, Cognition Therapeutics Inc. seems to lay the groundwork for further upside potential in the market.

Analysis of Stock Movement: What’s Next?

The affirmation of collaboration with the FDA continues to be a linchpin in the investor narrative. Alongside the drug’s promising results published in different clinical settings, CGTX is riding a wave of optimism.

If these encouraging developments continue, CGTX might be well-positioned to become a leading entity in transformative Alzheimer’s treatments. While it’s important to exercise due diligence, the confluence of positive news and stock momentum suggests that CGTX could potentially rise, fascinating traders and stakeholders worldwide.

In Conclusion

The sentiment surrounding Cognition Therapeutics’ recent progress embodies trader optimism. While the company’s financials present both challenges and opportunities, their tactical focus on disruptive research presents a compelling case for future growth. If these early indicators are anything to go by, CGTX holds promise — not just as a stock to watch, but as a potential cornerstone in the battle against debilitating diseases like Alzheimer’s. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” This wisdom resonates with those monitoring CGTX, underlining the importance of strategic trading decisions.

With an engaging trail ahead, maintain vigilance and keep abreast of further updates, as CGTX continues to chart its promising path forward.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”